Premium
P1‐259: SEX DIFFERENCES IN CEREBROSPINAL FLUID BIOMARKER CONCENTRATIONS ACROSS CLINICAL STAGES OF ALZHEIMER'S DISEASE
Author(s) -
Mofrad Rosha Babapour,
Tijms Betty M.,
Scheltens Philip,
Flier Wiesje M.,
Sikkes Sietske A.M.,
Teunissen Charlotte E.
Publication year - 2018
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2018.06.265
Subject(s) - biomarker , cerebrospinal fluid , bonferroni correction , apolipoprotein e , medicine , clinical significance , dementia , pathological , cohort , disease , sex characteristics , statistical significance , cognitive impairment , oncology , psychology , biology , biochemistry , statistics , mathematics
(A-N+T+, 8%), altered total Tau in 49 (A-N+T-, 11%) and isolated phospho-Tau alterations in 10 cases (A-N-T+, 2%). Conclusions: In the biomarker-based classification of MCI patients, some discrepancies exist regarding staging, nomenclature and interpretation of CSF findings. In this study, we partially replicated previous findings reporting a consistent rate (21%) of MCI patients showing abnormal values of Tau and phospho-Tau without any sign of amyloidosis, defined as Suspected Non-Amyloid Pathology (SNAP). SNAP may represent an entity underlying heterogeneous pathophysiologic processes. Clinical follow-up is mandatory in order to interpret these CSF findings.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom